Navigation Links
The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
Date:12/12/2013

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9 billion in 2012 to over $7 billion in 2022. The approval of three immunotherapies, the entry of second generation ALK and EGFR inhibitors, as well as continued uptake of Pfizer's Xalkori and EGFR inhibitors particularly in the advanced/metastatic first-line treatment setting will drive the growth of the NSCLC drug market. This market growth will occur despite the generic erosion of key branded current therapies including Eli Lilly's Alimta and Genentech/Roche/Chugai/Astellas's Tarceva.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor Non-Small-Cell Lung Cancer advisory service also finds that treatment of NSCLC is becoming increasingly personalized, driven by the accumulation of positive data of current and novel therapies in molecularly defined populations. The expected approvals of Novartis's ceritinib (LDK-378) and Chugai/Roche's alectinib for Xalkori-treated patients further advances the personalized treatment approach in NSCLC, offering a targeted second-line standard-of-care therapy for ALK-translocation positive patients.

"The majority of the agents in the NSCLC pipeline are being developed to target specific molecular targets," said Decision Resources Business Insights Analyst Orestis Mavroudis-Chocholis, Ph.D. "In the next ten years, we expect the launch of seven agents positioned to treat specific molecularly defined patient subpopulations—Pfizer's dacomitinib, Genentech/Roche/Chugai's onartuzumab, ce
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
9. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
10. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today its results for the ... Pat Mackin, Chairman, President and Chief Executive ... on our growth strategy with solid progress on several ... plans to transition to a direct sales model in ...
(Date:7/28/2015)... -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) announced ... quarter and year-to-date 2015 financial results on Tuesday, August ... markets. The earnings press release will be accessible through ... www.anipharmaceuticals.com . Arthur S. Przybyl , ... Arnold , Vice President and Chief Financial Officer, also ...
(Date:7/28/2015)... HACKENSACK, N.J., July 28, 2015  Champions Oncology, Inc. ... solutions and services to personalize the development and use ... the year ended April 30, 2015. Fourth ... increased 32% over the same prior year period result ... than 140 implants Joel Ackerman, Champions Oncology ...
Breaking Medicine Technology:CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11
... 19, 2007 - Amgen,(NASDAQ: AMGN) today ... study", a,randomized, double-blind, placebo-controlled, multicenter Phase ... 600 previously untreated,patients with extensive-stage small-cell ... study demonstrated,no statistically significant difference in ...
... Biomolecular Sciences Conference, THE WOODLANDS, Texas, April ... that data was presented,today highlighting potential therapeutic ... at the Society for Biomolecular,Sciences 13th Annual ... discoveries were made in a collaboration,between Lexicon ...
Cached Medicine Technology:Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5
(Date:7/28/2015)... ... July 28, 2015 , ... ADLINK Technology, a leading ... devices that enable the Internet of Things (IoT), announced its new medical panel ... provide exceptional computing power and multitasking capabilities. The MLC 4-21 is completely fanless, ...
(Date:7/28/2015)... Boulder, Colorado (PRWEB) , ... July 28, 2015 , ... ... music, with inspiration taken from influences around the world, in this collection of serene, ... deeply relaxing backgrounds for sleep, for yoga practice, for body work and more -- ...
(Date:7/28/2015)... ... July 28, 2015 , ... According to Kxan on June 24th ... addiction in lab mice. The study involving isradipine has garnered national attention and is ... their clients overcome drug and alcohol addictions. The study was conducted by the University ...
(Date:7/28/2015)... ... 28, 2015 , ... Bipolar disorder is often associated with mood swings ranging ... a year. The World Health Organization (WHO) has reported that bipolar disorder affects about ... reveals that the United States has the highest lifetime rate of bipolar disorder at ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
Breaking Medicine News(10 mins):Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 2Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 3Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 4Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3
... as Liaison Counsel and taking active roles in the Federal Court ... nephrogenic systemic fibrosis . The Federal Judge presiding over these ... , ... Cleveland, Ohio (PRWEB) March 25, 2009 -- Since ...
... wombs over several assisted reproduction cycles that use both ... than transferring two or more embryos at one time, ... of patients who choose to have only one embryo ... , The authors of the Finnish study published online ...
... In keeping with its mission to provide ... administrators and board members, Educators Health Alliance (EHA) ... Advocate. This individual will provide cost-effective methods for ... district employees who participate in the plan. The ...
... ALLEGAN, Mich., March 24 Perrigo Company (Nasdaq: ... received final approval from the U.S. Food and Drug ... The product has been determined to be therapeutically equivalent ... is indicated for the topical treatment of acne. Klaron(R) ...
... strains covered by the shot, study finds , , TUESDAY, March ... in New Mexico in the 1980s and 1990s contained DNA ... (HPV18), says a new study. , It also found that ... of five years younger than those diagnosed with cancers associated ...
... Patients with larynx cancer who received a three-drug combination ... were more likely to retain larynx function than were ... to data from a randomized controlled trial in the ... the National Cancer Institute. , Patients with locally ...
Cached Medicine News:Health News:Cleveland Trials Set In Nephrogenic Systemic Fibrosis (NSF) Gadolinium MRI Side Effects Cases 2Health News:Cleveland Trials Set In Nephrogenic Systemic Fibrosis (NSF) Gadolinium MRI Side Effects Cases 3Health News:Cleveland Trials Set In Nephrogenic Systemic Fibrosis (NSF) Gadolinium MRI Side Effects Cases 4Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 2Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 3Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 4Health News:Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion) 2Health News:HPV Data May Aid Vaccine's Effectiveness 2Health News:3-drug chemotherapy combination increases organ preservation in patients with larynx cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: